Gain Therapeutics
@gaintherapeutics.com
Discover Gain Therapeutics' next-gen allosteric small molecule therapies, combining physics-based methods and AI to address critical patient needs.
Gain Therapeutics's Company Logos
Gain Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#F16521
Flamingo
241, 101, 33
20, 88, 54
0, 58, 86, 5
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#1E4F58
Blue Dianne
30, 79, 88
189, 49, 23
66, 10, 0, 65
About Gain Therapeutics
Gain Therapeutics is a leading company in the field of drug discovery, focusing on creating new treatment options for difficult-to-treat disorders characterized by protein misfolding, including lysosomal storage disorders. Protein misfolding is a fundamental issue in various diseases, such as lysosomal storage disorders and certain neurodegenerative diseases like Parkinson's. When proteins misfold, their structure is disrupted, leading to impaired functionality.
Gain Therapeutics is revolutionizing drug discovery with its SEE-Tx™ target identification platform, which identifies and optimizes allosteric binding sites that have never been targeted before. This innovative approach unlocks new possibilities for treatment. While existing treatments for these disorders have significant limitations, Gain Therapeutics is dedicated to finding innovative solutions.
Founded in 2017, the company has received funding and support from prestigious institutions and organizations such as The Michael J. Fox Foundation for Parkinson’s Research. With a team of experienced professionals and a focus on scientific excellence, Gain Therapeutics is at the forefront of developing groundbreaking therapies
Company type
Public Company
Year founded
2017
Company size
11-50 employees
